So if 149 patients is statistically significant, why does the study require 208 patients? It doesn't. ICO's telegraphing that the study can be completed without any new patients. Enrolling patients can sometimes be a bottleneck for study completion. This is a significant milestone. It's also good to hear that there were no adverse effects in this group of patients.
Too bad we didn't get any efficacy data, but I suppse the suspense of what will be announced in q2 will help keep the share price up.
I will have a more complete update on my website this week.